GHK-Cu Half-Life: ~0.5–1 Hour (Estimated) — Pharmacokinetics & Evidence Review

GHK-Cu (glycyl-L-histidyl-L-lysine copper, a copper peptide complex) has an estimated plasma half-life of approximately 0.5–1 hour based on peptide class pharmacokinetics^[1]. No published human pharmacokinetic study has formally characterized its half-life, Tmax, or volume of distribution. GHK-Cu is an endogenous tripeptide (Gly-His-Lys) complexed with Cu²⁺ that promotes wound healing, collagen synthesis, and anti-inflammatory gene expression. Widely used as a cosmetic ingredient (topical) and studied for systemic wound healing applications (subcutaneous, research only). All systemic efficacy data is from animal studies or in vitro models — no FDA approval for systemic use; not approved for human therapeutic administration.

Quick Reference — GHK-Cu Pharmacokinetics

What Is the Half-Life of GHK-Cu?

GHK-Cu is a naturally occurring tripeptide (Gly-His-Lys) complexed with Cu²⁺ that was first isolated from human plasma albumin. Pickart et al. (2008, PMID 18690916)^[1] comprehensively reviewed GHK-Cu's biological activities, establishing its roles in wound healing, collagen synthesis, anti-inflammatory signaling, and superoxide dismutase upregulation across multiple in vitro and animal study systems. This review is the foundational evidence for GHK-Cu's mechanism but does not characterize pharmacokinetic parameters.

The estimated plasma half-life of 0.5–1 hour for the systemic peptide component is derived from peptide class characteristics: as a tripeptide with molecular weight approximately 340 Da (peptide alone), GHK is susceptible to rapid clearance via circulating serum aminopeptidases, dipeptidases, and glomerular filtration. The Cu²⁺ component (released during peptide degradation) enters systemic copper homeostasis — binding ceruloplasmin (~15%) and albumin (~70%) in plasma, with hepatic storage governing elimination — and follows copper-specific kinetics (days) rather than peptide pharmacokinetics. This dual-component picture makes GHK-Cu pharmacokinetically more complex than simple small-molecule drugs or single-peptide compounds.

Topical vs Systemic GHK-Cu — Two Different Pharmacokinetic Profiles

GHK-Cu is used in two fundamentally different contexts. In cosmetic formulations (topical), GHK-Cu is applied to skin to achieve local dermal collagen synthesis, wound healing, and anti-aging effects. Topical application achieves local dermal concentrations without significant systemic absorption — the peptide enters skin layers and exerts local effects, but crosses into systemic circulation minimally. For topical use, systemic plasma half-life is largely irrelevant; what matters is local tissue concentration and persistence^[1].

For subcutaneous injection (research use only), GHK-Cu achieves systemic plasma levels. In this context, the estimated peptide half-life of 0.5–1 hour applies. Research protocols using subcutaneous GHK-Cu aim for systemic tissue distribution for broader wound healing or anti-inflammatory effects. The two routes must not be confused in pharmacokinetic discussions.

Plasma Half-Life vs Biological Effect Duration

GHK-Cu's biological effects substantially outlast its estimated peptide plasma half-life. TGF-β-mediated collagen synthesis programs, VEGF-dependent angiogenesis, metalloproteinase (MMP) expression modulation, and superoxide dismutase upregulation are all transcriptional and enzymatic programs that persist for hours to days after the initiating GHK-Cu signal has cleared from plasma^[1]. Additionally, the Cu²⁺ deposited in tissues continues to act as a cofactor for copper-dependent enzymes well beyond plasma peptide clearance.

How Long Does GHK-Cu Stay in Your System?

Based on the estimated peptide half-life of 0.5–1 hour, the Gly-His-Lys component is expected to clear systemically within approximately 2.5–5 hours after the last dose. The Cu²⁺ component follows copper homeostasis on a substantially longer timescale:

After a Single Dose

After subcutaneous injection, the peptide component is absorbed into systemic circulation (15–30 min absorption phase), reaches Tmax approximately 30–60 minutes post-injection, then clears over 2–5 hours. Biological effects (collagen upregulation, anti-inflammatory signaling, angiogenesis) persist for 12–48 hours or longer through cascade mechanisms. The Cu²⁺ component persists on a days-long timescale. No human data exists for this timeline.

Dosing Implications of GHK-Cu's Estimated Half-Life

Why Daily Application for Topical, Variable Frequency for Systemic?

For topical cosmetic use, once or twice daily application replenishes local dermal peptide concentrations as the peptide is metabolized in skin. For systemic research protocols, dosing frequency is empirically determined — not pharmacokinetically optimized. Because GHK-Cu's biological effects (TGF-β, VEGF, MMP modulation) outlast plasma half-life through cascade mechanisms, dosing frequency for systemic use is tied to biological effect replenishment rather than plasma trough management^[1].

GHK-Cu vs Recovery Peptide Comparators

Pharmacokinetics by Route of Administration

Detection Window

Standard Drug Test Panels

GHK-Cu is not detected by standard workplace urine drug screens, WADA anti-doping panels, or any broadly deployed drug testing platform. Standard immunoassay drug tests target specific controlled substance classes and have no cross-reactivity with copper peptide compounds. GC-MS confirmation panels do not include GHK-Cu.

Specialized Testing (LC-MS/MS)

No published forensic detection study has characterized the urinary detection window for GHK-Cu. GHK-Cu is an endogenous peptide naturally present in human plasma at picomolar concentrations — distinguishing exogenous administration from endogenous levels requires sophisticated baseline comparison methodology that has not been published for this compound. GHK-Cu is not on WADA's monitoring program as of May 2026.

Mechanism — Why Does GHK-Cu Have This Estimated Half-Life?

GHK-Cu's rapid estimated peptide clearance stems from molecular simplicity. Gly-His-Lys (MW ~340 Da) is a small, unmodified tripeptide with no structural defenses against proteolytic degradation. Circulating serum aminopeptidases, dipeptidases, and endopeptidases can cleave the tripeptide within minutes of systemic exposure. The small molecular weight also enables glomerular filtration. These two clearance mechanisms — proteolytic degradation and renal filtration — predict a peptide plasma half-life in the range of 30–60 minutes^[1].

The Cu²⁺ component follows entirely different pharmacokinetics. After GHK-Cu delivers copper to tissue or is degraded systemically, the released Cu²⁺ rapidly binds plasma proteins — primarily albumin (~70%) and ceruloplasmin (~15%) — and enters the copper homeostasis cycle. Hepatic copper storage, incorporation into copper-dependent enzymes, and biliary excretion govern copper elimination over days. GHK-Cu therefore acts as a targeted copper delivery vehicle: the peptide provides the tissue-targeting vector; the copper provides sustained enzymatic cofactor activity.

Pickart et al. (2008)^[1] established GHK-Cu's biological activity across multiple repair pathways: TGF-β-mediated collagen synthesis and maturation; VEGF and bFGF upregulation for angiogenesis; MMP-1, MMP-2, and TIMP modulation for extracellular matrix remodeling; and superoxide dismutase stimulation for antioxidant defense. These are sustained enzymatic and transcriptional programs — not transient receptor occupancy effects — explaining why biological effect duration (12–48+ hours) substantially exceeds the estimated 0.5–1 hour peptide plasma half-life. The peptide initiates the cascade; the cascade and the delivered copper sustain the effect.

Frequently Asked Questions

• What is the half-life of GHK-Cu?
  GHK-Cu's plasma half-life has not been formally established in a published human pharmacokinetic study. Based on peptide class characteristics (tripeptide Gly-His-Lys, MW ~340 Da, no structural modifications), the peptide component is estimated to clear in approximately 0.5–1 hour. The Cu²⁺ component enters copper homeostasis and persists for days. Data quality: Animal/In-vitro — no formal PK study exists as of May 2026.
• How long does GHK-Cu stay in your system after stopping?
  The peptide (Gly-His-Lys) is estimated to clear within approximately 2.5–5 hours (5 × estimated half-life of 0.5–1 hour). The Cu²⁺ component enters copper homeostasis and may persist for days. Biological effects (collagen synthesis, angiogenesis, anti-inflammatory signaling) persist for 12–48+ hours through downstream cascade mechanisms (Pickart et al. 2008, PMID 18690916). No human clearance data exists.
• How does GHK-Cu's half-life affect dosing frequency?
  Topical: once or twice daily replenishes local dermal concentrations. Systemic research protocols: frequency is empirically determined, not pharmacokinetically optimized. Because TGF-β, VEGF, and MMP cascade effects outlast plasma clearance, dosing frequency for systemic use reflects biological effect replenishment rather than plasma trough management.
• Can GHK-Cu be detected on a drug test?
  GHK-Cu is not detected by standard workplace urine screens or WADA anti-doping panels. No published forensic detection study has characterized GHK-Cu's detection window. GHK-Cu is an endogenous peptide naturally present in human plasma, complicating exogenous detection methodology. Standard drug tests will not detect GHK-Cu.
• What is the difference between GHK-Cu's plasma half-life and how long its effects last?
  Estimated peptide plasma half-life: ~0.5–1 hour. Biological effect duration: 12–48+ hours via TGF-β-mediated collagen synthesis, VEGF angiogenesis, MMP modulation, and superoxide dismutase upregulation (Pickart et al. 2008, PMID 18690916). Cu²⁺ deposited in tissues acts as enzyme cofactor on a days-long timescale independent of peptide plasma levels. The plasma half-life describes molecular clearance; the biological effect duration reflects sustained transcriptional and enzymatic programs.
• How does GHK-Cu compare to BPC-157 in terms of half-life?
  GHK-Cu estimated peptide half-life: ~0.5–1 hour (inferred; no formal study). BPC-157 measured half-life: ~15 minutes in rat studies (Xu et al. 2022, PMC9794587). Both are research compounds with animal/in-vitro evidence and no formal human PK studies. GHK-Cu targets TGF-β and collagen synthesis; BPC-157 targets VEGFR2 and Akt-eNOS. Both exhibit PK/PD dissociation where biological effects substantially outlast plasma clearance.
• What is the difference between topical and systemic GHK-Cu pharmacokinetics?
  Topical: local dermal concentrations, limited systemic absorption, plasma half-life largely irrelevant — local tissue persistence governs effect duration. Primary use: cosmetic skin remodeling. Systemic SC injection (research only): achieves plasma levels with estimated peptide half-life ~0.5–1 hour; aims for broader tissue distribution. Two routes produce fundamentally different effect profiles: topical for skin; systemic for broader wound healing or anti-inflammatory endpoints.
• What does the copper (Cu²⁺) component of GHK-Cu do?
  Cu²⁺ in GHK-Cu serves as cofactor for copper-dependent enzymes: lysyl oxidase (collagen and elastin cross-linking), superoxide dismutase (antioxidant defense), and cytochrome c oxidase (mitochondrial respiration). After peptide degradation, released Cu²⁺ binds ceruloplasmin and albumin and enters copper homeostasis with days-long kinetics. This copper delivery to tissue amplifies and sustains wound healing effects initiated by the GHK peptide-receptor interaction — creating a dual mechanism: peptide-initiated signaling cascade plus copper-mediated enzymatic enhancement (Pickart et al. 2008, PMID 18690916).

References

• [1] Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Curr Aging Sci. 2008;1(3):200–209. PMID 18690916. PMID 18690916

Related Compounds